Table 5 Preferred choices of physicians for first systemic chemotherapy, in patients not eligible for cisplatin
Usual physician chemotherapy regimen for 1st line anticancer systemic therapy in patients ineligible to receive cisplatin | Set of Physicians N = 51 |
|---|---|
As neoadjuvant or adjuvant chemotherapy | |
Missing | - |
Single agent | - |
Chemotherapy doublet | 43 (84.3 %) |
Gemcitabine-carboplatin | 40 (78.4 %) |
Paclitaxel-carboplatin | 1 (2.0 %) |
Docetaxel-carboplatin | 1 (2.0 %) |
Gemcitabine-Paclitaxel | 1 (2.0 %) |
Other | 1 (2.0 %) |
None | 7 (13.7 %) |
As palliative first-line chemotherapy | |
Missing | - |
Single agent | 2 (3.9 %) |
Gemcitabine | 2 (3.9 %) |
Carboplatin (carboplatin) | - |
Chemotherapy doublet | 49 (96.1 %) |
Gemcitabine-carboplatin | 44 (86.3 %) |
Paclitaxel-carboplatin | 2 (3.9 %) |
Docetaxel-carboplatin | 1 (2.0 %) |
Gemcitabine-Paclitaxel | 1 (2.0 %) |
Other | 1 (2.0 %) |